Program. NSGO-CTU Biannual Investigator Meeting 30 November
|
|
- Sophia King
- 5 years ago
- Views:
Transcription
1 Nordic Society of Gynaecological Oncology Clinical Trial Unit Program NSGO-CTU Biannual Investigator Meeting 30 November Bella Sky Hotel, Center Blvd. 5, 2300 København S This meeting is partly sponsored by several pharma companies
2 Friday 30 November Registration Welcome, Mansoor Raza Mirza, NSGO-CTU Future plans and status report of NSGO-CTU activities, Mansoor Raza Mirza, NSGO-CTU 08:45 08:50 GDPR update, Joan Løhndorf, NSGO-CTU Surgical trials Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact Chair: Johanna Mäenpää, Tampere, Finland Overview of Surgical trials: - AGO-OVAR OP.4/DESKTOP III - LION - AGO OVAR OP.7/AGO OVAR 19/TRUST Johanna Mäenpää, Tampere, Finland AGO OVAR OP.7/AGO OVAR 19/TRUST A multicenter prospective randomized study of primary radical vs. interval debulking surgery for advanced ovarian cancer Berit Jul Mosgaard, Copenhagen, Denmark Panel discussion Ulla Puistola, Oulu, Finland Päivi Lindvall Kannisto, Lund, Sweden Ingvild Vistad, Kristianssand, Norway Yun Wang, Oslo, Norway First line trials - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome Chair: Elisabeth Åvall Lundqvist, Linköping, Sweden Overview of First line trials: - ENGOT Ov-15/AGO-OVAR 17/GINECO OV118/BOOST - ENGOT OV-23/EWOC-1 - AGO-OVAR12 - OVAR16 - PRIMA - ENGOT-ov25/PAOLA-1 - ENGOT-ov39/IMagyn050 - ENGOT-ov44/First - DUO-O - ENGOT-ov45/NCRI/ATHENA Elisabeth Åvall Lundqvist, Linköping, Sweden
3 COFFEE ENGOT-ov44/First - An adaptive Randomized Phase 3 Comparison of Standard Platinum Based Treatment Versus Platinum and TSR-042 followed by Niraparib and TSR-042 maintenance Therapy in Patients with pithelial Stage III or IV Cancer of the Ovary, Fallopian Tube, or Peritoneum Johanna Mäenpää, Tampere, Finland DUO-O - Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab and olaparib in newly diagnosed advanced ovarian cancer patients Jørn Herrstedt, Roskilde, Denmark ENGOT-ov45/NCRI/ATHENA - A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum- Based Chemotherapy Lars Fokdal, Århus, Denmark Panel discussion Henna Karkkainen, Kuopio, Finland Relapsed disease - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome Chair: Annika Auranen, Tampere, Finland Overview of trials where platinum is an option: - INOVATYON - NOVA - ENGOT-OV24-NSGO/AVANOVA - ENGOT-ov38/OReO - ENGOT-ov34/2.29 Annika Auranen, Tampere, Finland NOVA - A phase 3 randomized double-blind trial of maintenance with Niraparib versus placebo in patients with platinum sensitive ovarian cancer Olesya Solheim, Oslo, Norway ENGOT-OV24-NSGO/AVANOVA - Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer Maria Dimoula, Göteborg, Sweden ENGOT-ov38/OReO - A Phase IIIb, Randomised, Double-blind, Placebo-controlled,
4 Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy Mansoor Raza Mirza, Copenhagen, Denmark ENGOT-ov34/2.29 Atezolizumab in combination with Bevacizumab and Chemotherapy versus Chemo-Bevacizumab standard in recurrent ovarian cancer a randomized Phase III trial Gabriel Lindahl, Linköping, Sweden Panel discussion Synnöve Staff, Tampere, Finland Hanna Dahlstrand, Uppsala, Sweden Relapsed disease - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome Chair: Line Bjørge, Bergen, Norway LUNCH Overview of trials where platinum is NOT an option: - Javalin - NSGO-OV-UMB1/ENGOT-OV30 - ENGOT-OV42-NSGO / AVANOVA-Immune1 - NiCCC Line Bjørge, Bergen, Norway NSGO-OV-UMB1/ENGOT-OV30 - A multicenter, phase 2, open-label non-randomized study to obtain preliminary evidence of efficacy of several novel combinations in relapsed ovarian cancer. This information regards Cohorte A, MEDI9447 and Duvalumab Jon Røikjær Henriksen, Vejle, Denmark ENGOT-OV42-NSGO / BAN-ROC A randomized trial of atezolizumab, niraparib and bevacizumab combination versus standard of care for patients with recurrent ovarian cancer. Johanna Mäenpää, Tampere, Finland NICCC - A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium Bente Lund, Aalborg, Denmark Panel discussion Kristina Lindemann, Oslo, Norway
5 ENDOMETRIAL CANCER Endometrial Cancer - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome Chair: Mansoor Raza Mirza, Copenhagen, Denmark COFFEE ENGOT-EN2-DGCG A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer Caroline Lundgren, Stockholm, Sweden ENGOT-EN1/FANDANGO A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer Bengt Tholander, Uppsala, Sweden ENGOT-EN3-NSGO/PALEO A randomized, double-blind, placebo-controlled, phase II trial of Palbociclib in combination with Letrozole versus Placebo in combination with Letrozole for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer Gitte-Bettina Nyvang, Odense, Denmark ENGOT-EN6-NSGO/TSR A Phase 3 Randomized Open-Label Study of TSR-042, an anti-pd-1 Monoclonal Antibody, Versus Investigator s Choice Chemotherapy in Advanced/Recurrent Endometrial Cancer Nicoline Raaschou-Jensen, Herlev, Denmark Panel discussion Marjut Rintala, Turku, Finland Kathrine Woie, Bergen, Norway CERVICAL CANCER Cervical Cancer - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome Chair: Trine Jakobi Nøttrup, Copenhagen, Denmark Overview of Cervical Cancer trials: - ENGOT-Cx4 GINECO-CE106/Senticol III - ENGOT-CX7-NSGO/MaRuC - ENGOT-Cx10/GEICO 68-C/BEAT cc - ENGOT-cx6-NSGO/Tisotumab Trine Jakobi Nøttrup, Copenhagen, Denmark
6 Update of minimal invasive surgery trials (LACC, SENTICOL) Ane Gerda Zahl Eriksson, Oslo, Norway ENGOT-CX7-NSGO/MaRuC A randomized double-blind placebo-controlled phase II trial of Rucaparib maintenance therapy for patients with locally advanced cervical cancer Mansoor Raza Mirza, Copenhagen, Denmark ENGOT-Cx10/GEICO 68-C/BEAT cc - A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix Maarit Anttila, Kuopio, Finland ENGOT-cx6-NSGO/Tisotumab - A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax -TF-ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer Susanne Malander, Lund, Sweden Panel discussion Sinikka Oksa, Pori, Finland Vulvar CANCER Vulvar Cancer - Scientific rational, evidence for and study designs will be presented followed by a panel discussion to discuss potential impact of outcome Chair: Kristina Lindemann, Oslo, Norway 16: GROINSS-V - GRONINGEN INTERNATIONAL STUDY ON SENTINEL NODES IN VULVAR CANCER III - A PROSPECTIVE PHASE II TREATMENT TRIAL Kristina Lindemann, Oslo, Norway 16: Panel discussion Bengt Tholander, Uppsala, Sweden End of meeting Mansoor Mirza, NSGO NSGO-CTU will reimburse travel expenses maximum 200 Euros each for one investigator and one research nurse from an NSGO site + one single room at Hotel Bella Sky from November 2018, if these expenses are not covered by the hospital. Any expenses over 200 Euros + hotel single room cannot be reimbursed by NSGO-CTU.
Program. NSGO-CTU Biannual Investigator Meeting 30 November
Nordic Society of Gynaecological Oncology Clinical Trial Unit Program NSGO-CTU Biannual Investigator Meeting 30 November 2018 8.30-16.30 Bella Sky Hotel, Center Blvd. 5, 2300 København S This meeting is
More informationNSGO Annual Meeting 2019
Nordic Society of Gynaecological Oncology NSGO Annual Meeting 2019 Radisson Blu Scandinavia Hotel Amager Blvd. 70, 2300 Copenhagen Theme: Advances in the Management of Gynaecological Cancer Patients 27
More informationNSGO Annual Meeting 2019
Nordic Society of Gynaecological Oncology NSGO Annual Meeting 2019 Radisson Blu Scandinavia Hotel Amager Blvd. 70, 2300 Copenhagen Theme: Advances in the Management of Gynaecological Cancer Patients 28
More informationNSGO Annual Meeting 2019
Nordic Society of Gynaecological Oncology NSGO Annual Meeting 2019 Radisson Blu Scandinavia Hotel Amager Blvd. 70, 2300 Copenhagen Theme: Advances in the Management of Gynaecological Cancer Patients 27
More informationNordic Society of Gynaecological Oncology
Nordic Society of Gynaecological Oncology - from a Nordic interest group to a global leader in clinical trials Line Bjørge 14. mars 2017 I 1 Profile NSGO is a non-political, non-profit society Nordic platform
More informationNSGO SPONSORED Phase 2 Trials
Endometrial Cancer EN1 / FANDANGO EN3 / PALEO Ovarian Cancer AVANOVA AVANOVA-Immune1 OV-UMB1 Cervical Cancer MaRuC Ovarian Cancer OvaTIL for Cure Endometrial Cancer EN1 / FANDANGO EN3 / PALEO Ovarian Cancer
More informationPre-Congress Course on Radical Vulvar Surgery Tampere Surgical Education Centre (TSEC)
Wednesday 3 May 2017 08.00 14.00 Pre-Congress Course on Radical Vulvar Surgery Tampere Surgical Education Centre (TSEC) 12.00 15.00 Visit to the Helsinki University Central Hospital, Department of Radiotherapy
More informationNSGO Newsletter 1/2013
NSGO Newsletter 1/2013 FROM THE EDITOR The NSGO Newsletter is released twice a year. I hope you enjoy reading this update. There have been two important events for NSGO this spring. The Annual meeting
More informationNSGO Newsletter 1/2015
NSGO Newsletter 1/2015 WORDS FROM THE PRESIDENT Dear NSGO Members, This is my first Editorial as the President of NSGO, and at this point I like to thank my predecessor, professor Elisabeth Åvall- Lundqvist.
More informationNSGO Newsletter 1/2009
NSGO Newsletter 1/2009 Dear NSGO members, in its strategic meeting in September 2009, the NSGO Board decided to start publishing a Newsletter. Although NSGO has a great website (www.nsgo.org), a more personal
More informationThe OReO Study. Study design & Protocol Study design Key Inclusion criteria Patient population Recruitment and retention tools
The OReO Study A Phase IIIb, Randomised, Double-blind, Placebo-controlled, multi-centre Study of Olaparib Maintenance Re-treatment in Patients with Epithelial Ovarian Cancer Previously treated with a and
More informationESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY
ESMO PRECEPTORSHIP IN IMMUNO-ONCOLOGY LUGANO, MAY 4-5, 2018 Clinical development in ovarian cancer C. Sessa, CH CONTENT Rationale for immunotherapy in ovarian cancer Clinical data with single agent immune
More informationNSGO Newsletter 2/2012
NSGO Newsletter 2/2012 NEW NSGO NEWSLETTER EDITOR Kathrine Woie The NSGO newsletter is issued twice a year and highlights recent and upcoming events in the Society. I have now taken over as Editor after
More informationTRUST Trial on Radical Upfront Surgical Therapy
AGO OP.7 / TRUST TRUST Trial on Radical Upfront Surgical Therapy A close international cooperation ENGOT ov33 Ongoing Trials status update AGO-OVAR OP.7 / TRUST ENGOT-ov33 Trial setting: Sponsor: Pt with
More informationALIENOR GINECO-OV222/ENGOT-OV7
GCIG RARE TUMOUR COMMITTEE Closed Trial status update ISABELLE RAY-COQUARD ALIENOR GINECO-OV222/ENGOT-OV7 Trial setting: Sex chord-stromal ovarian tumors Study Design: Randomized, open label, phase II
More informationTarceva Trial EORTC 55041
Tarceva Trial EORTC 55041 Primary Chemotherapy Tarceva consolidation 2 years Control Patients closed / 835 Leading Participating EORTC AGO-AUSTRIA, ANZGOG, GINECO, MRC/NCIC, MANGO Randomised trial on Erlotinib
More informationTrial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer The safety and scientific validity of this study is the responsibility
More informationVirtual Journal Club. Ovarian Cancer. Reference Slides. Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies
Virtual Journal Club Ovarian Cancer Reference Slides Platinum-Sensitive Recurrent Ovarian Cancer: Making the Most of Emerging Targeted Therapies Mansoor R. Mirza, MD Copenhagen University Hospital Rigshospitalet
More informationBEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084. GCIG Meeting
BEATcc Trial: ENGOT-Cx10 / GEICO 68-C / JGOG1084 GCIG Meeting Ana Oaknin, MD PhD Head of Gynecologic Cancer Program. Vall d Hebron Institute of Oncology(VHIO). Vall d Hebron University Hospital. GEICO
More informationSelection of Sites & Feasibility Questionnaire Ovarian Front-Line Study
An Adaptive Randomized Phase 3 Comparison of Standard Platinum Based Therapy versus Platinum Therapy and TSR-042 Followed by Niraparib and TSR-042 Maintenance Therapy in Patients with Stage III or IV Cancer
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination
More informationCERVICAL/VULVAR CANCER CLINICAL TRIALS
CERVICAL/VULVAR CANCER CLINICAL TRIALS ALL-COMERS Primary Treatment Locally Advanced Recurrent Cervical GTFB (07-0935) TISSUE BANK ALL GYN TISSUE ETCTN (Phase II) (17-0458) LAO-MD017/#10010 Phase II Study
More informationCurrent GCIG Trials in Ovarian Cancer
Lead Grou p Log Current GCIG Trials in Ovarian Cancer Andres Poveda, MD GCIG Chair PARSGO Marrakech April 2018 History of GCIG Collaboration 1992 Collaboration on two studies of paclitaxel in ovarian cancer
More informationInhibidores de PARP en cáncer de ovario
Inhibidores de PARP en cáncer de ovario Ma Pilar Barretina Ginesta Servicio Oncología Médica Hospital Universitari Dr. J. Trueta Institut Català d Oncologia Coordinación científica: Dr. Fernando Rivera
More informationOVARIAN CANCER CLINICAL TRIALS
OVARIAN CANCER CLINICAL TRIALS FRONT-LINE THERAPIES STG III, IV PHASE 3 GOG 3015/Roche YO39523 (16-2745) Carbo/Taxol/Bev/Atezolizumab ECOG 0-2 Allows for primary cytoreductive surgery or interval debulking
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More informationOvarian Cancer. Georgia McCann, MD. Division of Gynecologic Oncology
Ovarian Cancer Georgia McCann, MD Division of Gynecologic Oncology Myth: Ovarian cancer is a silent killer Non-specific Abdominal pain, discomfort Bloating, back pain Urinary urgency Constipation Tiredness
More informationControversies in the Management of Advanced Ovarian Cancer
안녕하세요 Controversies in the Management of Advanced Ovarian Cancer Mansoor R. Mirza Nordic Society of Gynaecological Oncology (NSGO) & Rigshospitalet Copenhagen University Hospital, Denmark Primary Debulking
More informationTrial record 1 of 1 for:
Find Studies About Studies Submit Studies Resources About Site Trial record 1 of 1 for: YO39523 Previous Study Return to List Next Study A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel,
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Mars 2017 SEIN ADJUVANT OLYMPIA : A Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant therapy in BRCA mutated
More informationEORTC GCG MEETING 14 TH AND 15 TH OCTOBER 2011, AMSTERDAM. Location- Plesmanlaan 121. Phone: + 31 (0) FAX: +
EORTC GCG MEETING 14 TH AND 15 TH OCTOBER 2011, AMSTERDAM. NKI AVL ( THE NETHERLANDS CANCER INSTITUTE AND ANTONI VAN LEEUWENHOEK ZIEKENHUIS ) Location- Plesmanlaan 121 1066 CX Amsterdam Phone: + 31 (0)
More informationDr. Josep M. Del Campo Clínica Diagonal. Barcelona
Dr. Josep M. Del Campo Clínica Diagonal. Barcelona Nuevas Oportunidades en Cáncer de Ovario Cancer de Ovario: Es una enfermedad única? Cáncer de Ovario: Tratamiento actual Tratamiento inicial: sin cambios
More informationDrug Niraparib Olaparib
Dear NCCN Value Pathway Committee, We are making this submission to provide information that we believe is relevant for developing NCCN Categories of Preference for the use of PARP inhibitors in recurrent
More informationOVAIRES PROTOCOLES PTES PHASE DESCRIPTION
SERVICE DE GYNÉCOLOGIE-ONCOLOGIE PROTOCOLES EN RECRUTEMENT OVAIRES PROTOCOLES PTES PHASE DESCRIPTION OV25 DP/GSO/GSO/FG II PRÉVENTION A Randomized Phase II Double-Blind Placebo-Controlled Trials of Acetylsalicylic
More informationGCIG Rare Tumor Working Group Report. David M. Gershenson Isabelle Ray-Coquard
GCIG Rare Tumor Working Group Report David M. Gershenson Isabelle Ray-Coquard Thursday 31 st May 2012 Ted Trimble IRCI - Aims To facilitate the development of international clinical trials of treatments
More informationA phase II umbrella trial in patients with relapsed ovarian cancer
A phase II umbrella trial in patients with relapsed ovarian cancer NSGO-OV-UMB1 ENGOT-OV30 Sponsor: NSGO Relapsed ovarian cancer Treatment until disease progression A phase II umbrella trial in patients
More informationNCCN Guidelines for Ovarian Cancer V Meeting on 11/15/17
OV-1 External request: Submission from Vermillion/ASPiRA Laboratories to consider: Inclusion of the following recommendation in the workup for suspected ovarian cancer: OVA1 and/or Multivariate Index Assay
More informationPractical Guidance and Strategies for PARP Inhibition. Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy
Practical Guidance and Strategies for PARP Inhibition Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy Clinical Data Maintenance therapy : BRCA-mutated or all
More informationUpdate on PARP inhibitors: opportunities and challenges in cancer therapy
Update on PARP inhibitors: opportunities and challenges in cancer therapy Vanda Salutari Unità di Ginecologia Oncologica Fondazione Policlinico Universitario A. Gemelli vanda.salutari@policlinicogemelli.it
More informationESMO SUMMIT AFRICA. Latest evidence and current standard of care in advanced ovarian cancer. C.Sessa. Cape Town February 2018
ESMO SUMMIT AFRICA Latest evidence and current standard of care in advanced ovarian cancer C.Sessa IOSI, Bellinzona, CH Cape Town 14-16 February 2018 CONFLICT OF INTEREST DISCLOSURE None Ovarian carcinoma
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More informationMedical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia
Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)
More informationEndometrial Cancer Committee
Endometrial Cancer Committee REPORT to G.A. Chicago, May 2018 Chair: S. Greggi/Co-Chair: C. Creutzberg EN Committee Chicago, 31 May 2018 Closed Trials Status Update CLOSED TRIALS EC Newly Diagnosed or
More informationCzech Republic. Serbia Belarus
Czech Republic Slovakia Romania Ukraine Hungary Croatia Georgia Czech Republic Serbia Belarus Slovakia Hungary Slovenia Macedonia CEEGOG INTRODUCTION CEEGOG Central and Eastern European Gynecology Oncology
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationGOG-172: Survival Outcomes
CHEMOTHERAPY GOG-172: Survival Outcomes Progression-Free Survival Overall Survival Proportion Progression-Free 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 Rx Group IV IP PF Failed Total 50 160 210 63 142
More informationSummary... 2 GYNAECOLOGICAL CANCER Niraparib in second-line treatment for platinum sensitive recurrant ovarian cancer... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GYNAECOLOGICAL CANCER... 3 Niraparib in second-line treatment for platinum sensitive recurrant ovarian cancer...
More informationTeva Sweden AB Box Helsingborg
6 th Nordic MS Symposium Stockholm 26-27 January 2018 Teva Sweden AB Box 1070 251 10 Helsingborg SW/MEETING/17/0002 Okt-2017 6 th Nordic MS Symposium Gender Aspects and Comorbidities in Multiple Sclerosis
More informationSurgery in Recurrent Ovarian Cancer - an emerging area of evidence -
Surgery in Recurrent Ovarian Cancer - an emerging area of evidence - Andreas du Bois Kliniken Essen Mitte (KEM), Germany AdB 2018 A long and winding road to define the role of surgery in relapsed OC called
More informationInvestor Meetings October 2018
Investor Meetings October 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements
More informationTargeted Molecular Therapy Gynaecological Cancer Where are we now?
Targeted Molecular Therapy Gynaecological Cancer Where are we now? 0 T O M D E G R E V E S U B - S P E C I A LT Y F E L L O W G Y N A E C O L O G I C A L O N C O L O G Y U N I V E R S I T Y O F P R E T
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer
More informationPrincipal changes in clinical trials involving patients with Ovarian Cancer
Verona, 18.01.2019 Principal changes in clinical trials involving patients with Ovarian Cancer Principal changes in clinical trials involving patients with Ovarian Cancer Agenda 1. Patients: Biomarker
More informationTREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER
TREATMENT FOR RELAPSING PLATINUM SENSITIVE EPITHELIAL OVARIAN CANCER Sandro Pignata, MD, PhD Sabrina Chiara Cecere, MD Uro-Gynecological Department, Division of Medical Oncology, IRCCS National Cancer
More informationSymptom Benefit Committee. Chicago May 2018 F. Hilpert/JE Kurtz
Symptom Benefit Committee Chicago May 2018 F. Hilpert/JE Kurtz Symptom Benefit Committee Published studies SOLO 2-QoL accepted in Lancet Oncology NOVA-QoL submitted MOST questionnaire Update: ongoing studies
More informationA New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG
A New String to the Bow in the Treatment of Advanced Ovarian Cancer Bradley J. Monk, MD, FACS, FACOG Arizona Oncology (US Oncology Network) Professor, Gynecologic Oncology University of Arizona and Creighton
More informationLYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER
This announcement contains inside information 18 August 2017 07:00 BST LYNPARZA RECEIVES ADDITIONAL AND BROAD APPROVAL IN THE US FOR OVARIAN CANCER Lynparza's new tablet formulation approved as maintenance
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationLate recurrent epithelial ovarian cancer
Late recurrent epithelial ovarian cancer Dominic Richards University of Cape Town and New Somerset Hospital Gynaecological Oncology Unit September 2016 LATE RECURRENT EPITHELIAL OVARIAN CANCER Background
More informationImmune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group
Immune Therapy in Clear Cell Ovarian Cancer (ITICC) Hal Hirte Canadian Cancer Clinical Trials Group Results of Phase II Study of Durvalumab and Tremelimumab in recurrent clear cell ovarian cancer Trial
More informationNSGO CLINICAL TRIALS IN OVARIAN CANCER UPDATE
NSGO CLINICAL TRIALS IN OVARIAN CANCER UPATE Niraparib and niraparibbevacizumab combination against bevacizumab alone in Women with Homologous Recombination eficient (HR) platinumsensitive epithelial ovarian,
More informationJemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
More informationGOG212: Taxane Maintenance
GOG212: Taxane Maintenance Epithelial Ovarian or Primary Peritoneal Cancer Optimal or Suboptimal Cytoreduction Clinical C with normal CA125, no symptoms, normal CT Primary Carboplatin and Paclitaxel (or
More informationOVARIAN CANCER FACTSHEET. What is ovarian cancer?
OVARIAN CANCER FACTSHEET What is ovarian cancer? ENGAGe is releasing a series of factsheets to raise awareness of gynaecological cancers and to support its network to work at grassroots level. Ovarian
More informationMITO Phase III TRIALS. May 2009
MITO Phase III TRIALS Sandro Pignata MD PhD May 2009 Liposomal doxorubicin stealth vs carboplatin/paclitaxel in recurrent ovarian cancer patients with platinumfree interval between 6-12 months MITO 8 ENGOT
More informationWG Session : Incorporation of PROs in clinical trial. Digest of the OCC plenary session Recommendations? Publication?
WG Session : Incorporation of PROs in clinical trial Digest of the OCC plenary session Recommendations? Publication? Plenary Presentation Incorporating Patient Reported Outcomes in GCIG Ovarian Cancer
More informationCiti s 13 th Annual Biotech Conference September 5, 2018
Citi s 13 th Annual Biotech Conference September 5, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they
More informationlc Department of Gynecology, Helsinki University Hospital.
Annals of Oncology 9: 0-07. 998. 998 Kluwer Academic Publishers. Printed in the Netherlands. Original article Long-term results from a phase II study of single agent paclitaxel (Taxol ) in previously platinum
More informationExamestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)
Lindemann et al. BMC Cancer 2014, 14:68 RESEARCH ARTICLE Open Access Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology
More informationRecurrent Ovarian Cancer Phase 1b Results
Recurrent Ovarian Cancer Phase 1b Results December 5 th, 2017 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect Immunovaccine
More informationEORTC LUNG CANCER GROUP GROUP MEETING
Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00 Board meeting 11.00 11.30 Arrivals & Welcome coffee 11.30 11.50 Welcome & Introduction New Board,, Membership status, Calendar
More informationEligibility Form. 1. Patient Profile. (This form must be completed before the first dose is dispensed.) Request prior approval for enrolment
Bevacizumab in combination with Paclitaxel and Carboplatin - Frontline Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (This form must be completed before the first
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationEvaluation of Optimal Initial Treatment Duration of Bevacizumab in Combination With Standard Chemotherapy in Patients With Ovarian Cancer (BOOST)
1 von 5 26.03.2013 15:16 A service of the U.S. National Institutes of Health Trial record 1 of 1 for: Ago ovar 17 Previous Study Return to List Next Study Evaluation of Optimal Initial Treatment Duration
More informationThe Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture
The Role of PARP Inhibitors in Ovarian Cancer: An Emerging Picture This satellite symposium took place on 10 th September 2017 as part of the European Society for Medical Oncology (ESMO) Congress in Madrid,
More informationPost ASCO 2017 Gynækologisk kræft. Læge, PhD Zarah Zimling Onkologisk afdeling, Rigshospitalet.
Post ASCO 2017 Gynækologisk kræft Læge, PhD Zarah Zimling Onkologisk afdeling, Rigshospitalet. Endometrie cancer Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and
More informationPARP Inhibitors: Patients Selection. Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016
PARP Inhibitors: Patients Selection Dr. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau Formigal, June 23th 2016 OVARIAN CANCER (OC): MULTIPLES DISEASES Different types with different behaviour
More informationFDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors
FDA Companion Diagnostic Testing and Implications for Pharmacy and Medical Directors Diana Brixner, PhD, RPh, FAMCP Professor, University of Utah Health Sciences Executive Director, Pharmacotherapy Outcomes
More informationPARP Inhibitors for Ovarian Cancer: Effectiveness and Value
PARP Inhibitors for Ovarian Cancer: Effectiveness and Value Draft Voting Questions for September 14, 2017 Public Meeting These questions are intended for the deliberation of the Midwest CEPAC voting body
More informationPrecision Therapies. for. Women s Cancers
Precision Therapies for Women s Cancers 1 Company Snapshot Founded Q3 2016, a Delaware Incorporation Spin-out of Oncology Venture Aps, Denmark Seed of $3.5 million completed December, 2016 Focus: advancing
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationPrincipales presentaciones de AstraZeneca/MedImmune en el congreso de ESMO 2017
Principales presentaciones de AstraZeneca/MedImmune en el congreso de ESMO 2017 Autor principal Título del abstract Detalles de la presentación Cáncer de pulmón Paz-Ares L Ramalingam S Zhou C PACIFIC:
More informationAccelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO
Accelerating our priorities and building our capabilities in Oncology GSK to acquire TESARO 3 December 2018 Cautionary statements This presentation may contain forward-looking statements. Forward-looking
More informationPRELIMINARY PROGRAM (Version ) The 36 th Meeting of the Scandinavian Sarcoma Group
PRELIMINARY PROGRAM (Version 2012-09-28) The 36 th Meeting of the Scandinavian Sarcoma Group Helsinki Date: October 9-11, 2013 Place: Hotel Crowne Plaza Mannerheimentie 50 Helsinki 00260 Finland Hotel
More informationFALL MEETING. Sitges, 7th and 8th October, Venue. ME Sitges Terramar Hotel Passeig Marítim, Sitges, Barcelona
FALL MEETING Sitges, 7th and 8th October, 2018 Venue ME Sitges Terramar Hotel Passeig Marítim, 80 08870 Sitges, Barcelona Sunday 7 th October 2018 Time slot Topic / Title of presentation Chair 9.00 11.00
More informationNordic Shoulder and Elbow Conference
8th Triennial Nordic Shoulder and Elbow Conference 16-17 May 2019 International faculty COURSE CHAIRMAN: Ilkka Sinisaari VENUE: Clarion Hotel, Helsinki, Tyynenmerenkatu 2, Helsinki PROGRAMME NORDIC SHOULDER
More informationPutting NICE guidance into practice
Putting NICE guidance into practice Resource impact report: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationIn 2017, an estimated 22,240 women will
OVARIAN CANCER Ovarian cancer remains the most deadly gynecologic malignancy in the United States. What are the practice implications of recent research results on screening, neoadjuvant chemotherapy,
More informationHighlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women s Cancer
May 2017 Volume 15, Issue 5, Supplement 5 A SPECIAL MEETING REVIEW EDITION Highlights in Ovarian Cancer From the 2017 Society of Gynecologic Oncology Annual Meeting on Women s Cancer A Review of Selected
More informationDate Site Confirmed By Sponsor. Non- Confirmation Status. HRA Approval Date. Date Site Confirmed
Research Ethics Committee Reference Number Integrated Research Application System Number Submission Type Name of Trial First Patient Recruited? Date of First Patient Recruited Invited Selected Approval
More informationCurrent Medical Oncology Approaches to Gynecologic Cancers. Mihaela Cristea, MD Associate Professor Medical Oncology
Current Medical Oncology Approaches to Gynecologic Cancers Mihaela Cristea, MD Associate Professor Medical Oncology Nothing to disclose DISCLOSURE Ovarian Cancer Objectives: a. To discuss new FDA approved
More informationSyddansk Universitet. Publication date: 2015
Syddansk Universitet Safety and Efficacy of adding pegylated Interferon 2b to standard Dose Dasatinib in newly diagnosed CP-CML Hjort-Hansen, Henrik ; Stentoft, Jepser; Richter, Johan; Koskenvesa, Perttu;
More informationThe Clinical Research E-News
Volume 3: ISSUE 8: May 5, 2011 The Clinical Research E-News Jefferson Kimmel Cancer Network: For urgent clinical trial questions or assistance please page: 877-656-9004 Now Open: E2906, Phase III randomized
More informationThe Scandinavian Sarcoma Group annual report on extremity and trunk wall soft tissue and bone sarcomas
The Scandinavian Sarcoma Group annual report on extremity and trunk wall soft tissue and bone sarcomas 2012-2016 1 The SSG annual report on extremity and trunk wall soft tissue and bone sarcomas. The Scandinavian
More informationResults of a Phase II Trial of Selinexor, in Pa5ents with Gynaecological Cancers
Results of a Phase II Trial of Selinexor, in Pa5ents with Gynaecological Cancers Ignace Vergote 1, Bente Lund 2, Hanne Havsteen 3, Zaza Ujmajuridze 4, Els Van Nieuwenhuysen 1, CharloLe Haslund 2, Trine
More information11 th Working Groups Meeting of the Scandinavian Sarcoma Group
11 th Working Groups Meeting of the Scandinavian Sarcoma Group Scandinavian Sarcoma Group 1979 Version 2005-10-17 www.ssg-org.net ssg@med.lu.se November, 28-29, 2005 Copenhagen INTRODUCTION Welcome to
More information